Candidemia in a Preterm Neonate at Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, South West, Nigeria.

Ann Afr MedNov 5, 2025 (epub)
Case ReportPediatricsInfectious DiseasesOpen access

Olusola Adetunji Oyedeji, Muideen Abiodun Ogunyode, Bukola Adetutu Sayomi et al.

✦ AI-curated · Sources linked

Case in brief

A 36-week preterm, low-birth-weight male infant developed signs of neonatal sepsis shortly after vaginal delivery. His mother had untreated vaginal candidiasis around the time of delivery. The infant did not improve with the conventional antibiotics used locally for neonatal sepsis; blood culture subsequently grew Candida albicans. He improved after oral fluconazole therapy.

What made this case unusual

The report links neonatal candidemia with maternal untreated vaginal candidiasis and describes improvement with oral fluconazole after conventional antibiotics failed.

Diagnostic / clinical pearl

In a neonate with sepsis unresponsive to conventional antibiotics, blood culture can identify candidemia and guide recognition of Candida albicans infection.

Source

Published in Ann Afr Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.